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ABSTRACT
A commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-
immunogenic. However, many studies have reported that unexpected immune responses
have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid
clearance of PEGylated nanocarriers upon repeat administration, called the accelerated blood
clearance (ABC) phenomenon. ABC involves the production of antibodies toward nanocarrier
components, including PEG, which reduces the safety and effectiveness of encapsulated
therapeutic agents. Another immune response is the hypersensitivity or infusion reaction
referred to as complement (C) activation-related pseudoallergy (CARPA). Such immunogeni-
city and adverse reactivities of PEGylated nanocarriers may be of potential concern for the
clinical use of PEGylated therapeutics. Accordingly, screening of the immunogenicity and
CARPA reactogenicity of nanocarrier-based therapeutics should be a prerequisite before they
can proceed into clinical studies. This review presents PEGylated liposomes, immunogenicity
of PEG, the ABC phenomenon, C activation and lipid-induced CARPA from a toxicological
point of view, and also addresses the factors that influence these adverse interactions with
the immune system.
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Nanocarriers, such as liposomes and biodegradable poly-
meric nanoparticles are promising tools for targeted drug
delivery in treating cancer and many other diseases and
a number of them have received clinical approval for the
delivery of a variety of therapeutics [1–5]. They combine
the advantages of being biocompatible and relatively
nontoxic, and having an inherent ability to protect the
encapsulated payload from enzymatic degradation or
other unfavorable conditions [6,7]. In addition, they
have been shown to increase the therapeutic index of
encapsulated drugs and decrease their toxicity by altering
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the pharmacokinetic profile of the drugs [8,9].
Collectively, these advantages have led to the approval
of nanoscale drug carriers in a number of clinical settings
involving a variety of small molecule therapeutics and
recently siRNA. Nevertheless, the widespread utilization
of nanocarrier-based therapeutics in medicine is occa-
sionally constrained by concerns regarding potential
toxicities of the carrier.
Nanocarriers with certain physical and chemical
characteristics, in some circumstances in animal
experiments, have been reported to prime the host-
immune system, resulting in severe adverse effects
and/or lack of therapeutic efficacy of the encapsulated
drug [10–12]. For instance, surface electrostatic
charges and/or particle size of developed nanocarriers
are fundamental to define such immune responses
[13]. In these experiments, the nanoparticles are
essentially recognized as foreign particles by immune
cells, which induce multilevel immune responses. In
addition, the nanoparticles have been reported to
interact with circulating serum proteins, such as com-
plement proteins belonging to the primary humoral
immune system, resulting in their rapid systemic
clearance by the cells of mononuclear phagocyte sys-
tem (MPS) [14,15]. Mononuclear phagocyte system
(MPS), composed of dendritic cells (DCs), monocytes
and macrophages, is a part of the innate immune
system that plays a critical role in phagocytosis of
pathogen and foreign substances in all phases of the
immune response. Taken together, these interactions
with the immune system have the potential to influ-
ence the in vivo fate of administrated nanocarriers
and might impair their therapeutic performance.
PEGylation, the covalent linking of polyethylene
glycol (PEG) chains, is currently considered as an
effective approach to increase stability and prolong
liposomes in vivo circulation time. PEGylation has
been reported to hinder the adsorption of protein
opsonins in the circulation onto liposome surfaces,
which results in increased clearance of liposomes by
the mononuclear phagocytic cells in the liver and
spleen [16,17]. Consequently, PEGylation improves
the residence time of liposome, as well as encapsu-
lated therapeutic agents, in the circulation. In the
drug delivery field, PEGylated and non-PEGylated
liposomes have received a number of clinical
approvals. The most successful example of
a PEGylated liposomal formulation is Doxil®
(PEGylated liposomes encapsulating the anticancer
drug doxorubicin (DXR)), approved for Kaposi’s sar-
coma, ovarian cancer, breast cancer and multiple
myeloma [18–20]. Nevertheless, PEGylated liposomes
have caused some lipid-related side effects. Doxil®, in
some patients, caused immediate hypersensitivity
reactions upon first injection. A number of studies
confirmed the role of complement activation in ana-
phylactic reactions observed in up to 25%–45% of
patients treated with Doxil® upon the first injection
[12,21,22]. This reaction is well controlled by slowing
the rate of Doxil® infusion and giving the patient pre-
medications [23,24]. The hypersensitivity reaction is
rarely seen upon the second and subsequent injec-
tions of Doxil® [24].
2. Immunogenicity of PEG
Polyethylene glycol (PEG) is a bio-inert, thermoelastic
linear hydrophilic polymer with the molecular formula
(C2nH4n+2On+1). It is a non-toxic and non-ionic ether
diol with a GRAS (generally recognized as safe) desig-
nation and a growing use as a food additive and an
additive in pharmaceutical formulations. Over the past
decades, PEG has been considered to be non-
immunogenic. However, there is growing evidence
that PEG might be more immunogenic than previously
recognized. This is supported by the growing existence
of anti-PEG antibodies in healthy humans who are
increasingly exposed to PEG additives [25,26]. For
example, Armstrong et al. [27] reported the existence
of anti-PEG antibodies in 25% in healthy blood donors.
Later on, Yang and Lai [28] documented even higher
concentrations of anti-PEG antibodies in about 42% in
patients with no history of treatment with PEGylated
products. The higher prevalence of pre-existing anti-
PEG antibodies in healthy individuals, not receiving
PEG-containing drugs, is being attributed to the fre-
quent use of PEG-containing or PEG-coupled products
that are common ingredients in personal care, beauty,
and household cleaning products (e.g. soap, sunblock,
cosmetics), as well as processed foods. Accordingly,
Yang and Lai proposed a tentative mechanism for the
formation of PEG antibodies in which various condi-
tions like ulcerations, abrasions and skin tears may
result in local inflammatory reactions and induction
of immune responses in the presence of PEG. The
frequent use of products containing, or coupled to,
PEG, such as, soaps, shampoos, toothpastes, lotions,
or detergents, results in penetration of PEG to sites of
inflammation where contact with immune cells stimu-
lated the production of anti-PEG antibodies [28]. The
presence of pre-existing anti-PEG antibodies might
trigger further immunogenic responses to PEG when
the human subjects receive PEGylated therapeutics
[25,26]. These pre-existing and induced anti-PEG anti-
bodies together may compromise the response to
PEGylated medicines in the clinical settings [29–31].
3. Function of grafted PEG on nanocarriers
As described above, PEG has been used for surface
modification of nanocarriers such as liposomes,
nanoparticles and therapeutic proteins, to increase
their circulation half-lives [32–36]. It is reported
that PEG grafted on surfaces increases their
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hydrophilicity and functions as a steric barrier,
hindering the interactions between the nanocarriers
and serum protein opsonins that are involved in the
recognition of the carriers by the cells of MPS [17].
PEGylated nanocarriers such as PEGylated lipo-
somes, PEGylated micelles and PEGylated proteins
that are not prematurely taken up by the cells of
MPS have a greater chance of reaching, and deliver-
ing increased levels of therapeutics to target dis-
eased organs, compared to non-PEGylated one.
This could be attributed to the stealth property
imparted by PEGylation on nanocarrier surfaces
and consequently decreased uptake of PEGylated
nanocarriers by the cells of MPS, which explains
in part why they have received a number of clinical
approvals [1,19,37,38].
4. The accelerated blood clearance (ABC)
phenomenon against PEGylated liposomes
Dams et al. [39] introduced the concept of the acceler-
ated blood clearance (ABC) phenomenon in 2000 when
they showed that the first dose of PEGylated liposomes,
injected into rats and rhesus monkeys, caused enhanced
clearance of the second dose of PEGylated liposomes,
injected one week later. To date, this phenomenon has
not had serious implications for the clinical use of
PEGylated liposomal anticancer drug formulations
such as Doxil®, but may have implications for the use
of other types of PEGylated products in the future
where repeated administration is required in the clinical
setting. The increasing use of marketed products con-
taining PEG appears to be amplified the numbers of
patients exhibiting circulating pre-existing anti-PEG
antibodies (now approaching 50%), which can lead to
more unexpected immune-mediated side-effects and
decreased therapeutic effects during their clinical use
[40,41].
4.1 Mechanism of the ABC phenomenon
According to Dams et al. [39], in animal models,
a second dose of PEGylated liposomes, injected within
a time interval of 5 and 21 days, was cleared very rapidly
from the blood circulation. The ABC phenomenon
showed two distinct phases: the induction phase and
the effectuation phase. The induction phase followed
the initial dose of PEGylated liposomes in which the
biological system is ‘primed’. The effectuation phase
occurs at day 3–7 after the initial dose in which
a subsequent dose of PEGylated liposomes is rapidly
cleared from systemic circulation [42].
Dams et al. [39] demonstrated that serum transfu-
sions into normal rats from rats pretreated with
PEGylated liposomes also elicited the enhanced blood
clearance of a first dose of PEGylated liposomes. In
addition, they reported that the phenomenon was
abolished either when the rat serum was preheated at
56°C for 30 min prior to transfusion, which inactivate
complement system, or when antibodies in the rat
serum were removed by other means. These results
support the existence of a circulating opsonizing factor
that is a heat labile non-antibody molecule, which
results in the rapid clearance of a second dose via
phagocytosis by liver macrophages [39].
Our group has been intensively studying the
mechanism behind the ABC phenomenon. We have
confirmed that the ABC phenomenon against
PEGylated liposomes occurred in mice [43], rats
[43], minipigs [44] and beagle dogs [45] for empty
liposomes (containing no drug). We further showed
that anti-PEG IgM production and the resulting ABC
phenomenon triggered by PEGylated liposomes
occurred in BALB/c nu/nu (T cell-deficient) mice,
but not in SCID (T and B cells-deficient) mice.
A similar observation was reported by Semple et al.
[46] with nude and SCID-Rag2 mice. They showed
that B cells and immunoglobulins, but not T cells, are
critical in the development of immune responses
against PEGylated liposomes containing oligonucleo-
tides. These data prove that anti-PEG IgM, produced
by the splenic B cells that are independent of T-cell
involvement, could play a significant role in the
induction of the ABC phenomenon.
The so-called class-2 of thymus-independent antigens
(TI-2) may provide an additional explanation for the
mechanism of the ABC phenomenon induced by
PEGylated liposomes. TI-2 antigens can induce an
immunological response by extensively cross-linking
the cell surface immunoglobulins of specific B cells,
resulting in secretion of massive amounts of neutralizing
antibodies including IgM and IgG from the B cells
[47,48]. Cheng and co-workers [49,50] have demon-
strated that anti-PEG antibody (IgM) obtained following
immunization with PEGylated β-glucuronide recognizes
the repeating -(O-CH2-CH2)n- subunit (16 units) of
PEG. This raises the assumption that PEG polymer in
PEGylated nanocarriers acts as a TI-2 antigen and the
repeating subunit may be an immunogenic epitope of
PEG and a binding site for the derived anti-PEG IgM.
Based on all the above-mentioned reports, we con-
firmed that the ABC phenomenon is divided into two
phases: the induction phase and effectuation phase. In
the induction phase, the biological system is ‘primed’
by promoting the proliferation and differentiation of
specific B cells (responsible for the antibody produc-
tion and cell-mediated immune responses) in the
marginal zone of the spleen in T-cell independent
manner, resulting in anti-PEG IgM formation [51–
54]. The delayed effectuation phase is manifested
from day 5 to day 21 after the initial dose, which is
closely correlated with the time course for anti-PEG
IgM production in response to initial dose. In this
effectuation phase, a subsequent dose of PEGylated
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liposomes is rapidly opsonized by C3 fragments and
cleared from the systemic circulation by the Kupffer
cells in coordination with anti-PEG IgM and the
complement system, as shown in Figure 1. Further,
the magnitude of the ABC phenomenon is closely
linked to the magnitude of anti-PEG IgM production
by splenic B cells in response to an initial injected
dose of PEGylated liposomes [55,56]. However,
although removal of spleen from mice reduced anti-
PEG IgM production, it failed to completely reverse
the rapid clearance of PEGylated liposomes to normal
control levels. This suggests that another serum
factor(s) or cell(s) may contribute to this phenom-
enon [43].
Once the PEGylated liposomes (first dose) reach the
spleen, they bind and crosslink to surface immunoglo-
bulins on reactive B cells in the splenic marginal zone
and consequently trigger the production of an anti-PEG
IgM that is independent of T-cell help. Upon adminis-
tration of the second dose, if anti-PEG IgM, produced
in response to the first dose, still exists in the blood
circulation, it binds to the PEG on the liposomes, and
subsequently activates the complement system, result-
ing in opsonization by C3 fragments and enhanced
uptake by Kupffer cells via complement receptor-
mediated endocytosis.
4.2 Factors affecting the ABC phenomenon
There are many factors that have an impact on the
ABC phenomenon including: animal species, lipid
dose, time interval between injections, nanoparticle
physicochemical properties and type of encapsulated
drug (Figure 2).
4.2.1 Animal species
In various types of animal models (rats, rabbits, mice,
guinea pigs, minipigs and beagle dogs), repeated intra-
venous injection of PEGylated liposomes has been
reported to elicit the ABC phenomenon [39,42].
However, the magnitude of the elicited ABC phenom-
enon varied with the animal species. Suzuki et al. [44]
reported that anti-PEG IgM production and the ABC
phenomenon were not detected in mice treated with
Doxil® (2 and 20 mg DXR/m2), while in minipigs trea-
ted with Doxil® (2 mgDXR/m2), anti-PEG IgM produc-
tion and the ABC phenomenon were significantly
increased. Beagle dogs seemed to be more sensitive to
Doxil® than rodents in triggering anti-PEG IgM and the
ABC phenomenon [45]. This might be due to variations
in the sensitivity of the immune system between dogs
and rodents or due to differences in the pharmacoki-

















Figure 1. Representation of the sequence of events leading from anti-PEG IgM induction to accelerated clearance of PEGylated
liposomes.
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4.2.2 Lipid dose
There appears to be a strong inverse relationship between
the extent of the ABC phenomenon and the phospholi-
pid dose for the initial dose of PEGylated liposomes,
regardless of liposomal phospholipid composition. The
higher the lipid dose, the lower the ABC phenomenon
[57,58]. We speculate that low concentrations of phos-
pholipid could activate marginal zone B cells (MZ-B),
and trigger anti-PEG IgM production, while higher
initial doses of PEGylated liposomes could cause MZ-B
to elicit immunological tolerance or anergy [59,60]. MZ-
B cells are a specialized population of B cells that are
located in the marginal zone of the spleen. They secrete
antibodies that help to protect against blood-borne
viruses and bacteria. Rats injected intravenously with
doses higher than 5 μmol phospholipid/kg did not exhi-
bit increased levels of anti-PEG IgM and the subsequent
ABC phenomenon. On the other hand, the ABC phe-
nomenon was significantly increased at phospholipid
doses less than 1 μmol phospholipid/kg [58,61,62].
Such difference also might be due to difference in the
pharmacokinetics of PEGylated liposomes and/or reac-
tivity of MZ-B with PEGylated liposomes in different
species as described above.
4.2.3 Time interval between injections
The induction and the magnitude of the ABC phenom-
enon were dependent on the time between injections.
Some reports demonstrated that no alteration in the
clearance of encapsulated drugs was observedwith repeat
injections of PEGylated liposomes when the interval
between the initial and subsequent injection was less
than 2 days or more than 4 weeks [63,64]. Actually,
Dams et al. [39] and our group [51,53,58] showed that
the extent of the ABC phenomenon was highest when
the interval between two injections was from 4 to 7 days.
This could be explained by the fact that the production of
anti-PEG IgM occurred by 3–4 days after the initial dose
[54,57] and the IgM disappeared within its biological
half-life of 3 weeks [65].
4.2.4 Physicochemical properties of liposomes
The physicochemical properties of PEGylated liposomes
such as size, lipid composition, extent of PEGylation and
surface charge, all affected the extent of the ABC
phenomenon. It has been reported that ‘classical’ (non-
PEGylated) liposomes also induced the ABC phenom-
enon when PEGylated liposomes were given as
a subsequent dose [66]. We investigated the influence of
surface charge and liposome size on the occurrence of the
ABC phenomenon in mice. The ABC phenomenon was
not induced when the initial dose of liposomes exhibited
three different mean particle sizes (100, 400 and 800 nm)
and three different surface potentials (+13,15, – 46.15 and
−1.51mV) [66].On the other hand, the lipid composition
of the liposomes did affect the appearance of the ABC
phenomenon, e.g. use of phospholipids with long satu-
rated acyl chains and inclusion of membrane stabilizers
such as cholesterol and PEGylated lipid. In rats, the effect
of phospholipid types in the initial dose of PEGylated
liposomes on the ABC phenomenon was investigated
using five different types of phospholipids (hydrogenated
Figure 2. Representation of factors affecting the accelerated blood clearance phenomenon of PEGylated liposomes.
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soy phosphatidylcholine, egg sphingomyelin, soybean
phosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phos-
phocholine and egg phosphatidylcholine). All PEGylated
liposomes composed of different phospholipids signifi-
cantly induced the ABC phenomenon. The PEGylated
liposomes composed of unsaturated phospholipid
induced the phenomenonmore than the PEGylated lipo-
somes composed of saturated phospholipid [66,67].
4.2.5 Encapsulated drug
It has been reported that the drugs encapsulated in
PEGylated liposomes strongly affected the ABC phe-
nomenon. PEGylated liposomes containing anticancer
drugs such as DXR, oxaliplatin (l-OHP) and mitoxan-
trone result in no induction of the ABC phenomenon
[68–71]. We can hypothesize that chemotherapeutic
agents encapsulated in liposomes accumulate in immune
cells and hinder anti-PEG IgM production by inhibiting
B cell proliferation and/or by damaging B cells in the
marginal zone [70]. Indeed, there is no evidence that the
clinical use of Doxil® causes the ABC phenomenon.
However, Suzuki et al. [44] reported that intravenous
injection of Doxil® at very tiny doses (0.2 mg/m2) triggers
the ABC phenomenon in various animal species. These
small doses contain very low total doses of lipids and low
total doses of the drug. The low levels of DXR in small
amounts of injected Doxil® may be below the threshold
for inhibiting B cell secretion of anti-PEG IgM. A similar
observation was reported by Nagao et al. [57] who
demonstrated that intravenous injection of l-OHP-
containing PEGylated liposomes at low doses (0.023 μg
l-OHP/kg) could trigger a relatively high anti-PEG IgM
response. On the other hand, at higher doses of l-OHP-
containing PEGylated liposomes (2.3–2300 μg l-OHP/
kg), the l-OHP tended to inhibit the anti-PEG IgM
response. Hence, low doses of PEGylated liposomal for-
mulations in Phase 1 dose-escalation trials could concei-
vably induce anti-PEG IgM and the ABC phenomenon
confounding analysis of the Phase I pharmacokinetics.
Furthermore, since low total doses of lipids trigger the
ABC phenomenon to a greater extent than higher doses,
this may also play a role in Suzuki’s observations.
Recent reports have demonstrated that multiple injec-
tions of PEGylated liposomes containing topotecan in
beagle dogs and Wistar rats could trigger the ABC phe-
nomenon [72,73]. Topotecan is a cell cycle-specific drug
that exerts its inhibitory action in the S phase of the cell
cycle. One can hypothesize that topotecan might not
affect the B cell proliferation for B cells in other phases
of the cell cycle and still allow them to produce some
anti-PEG IgM. Another, more convincing hypothesis is
that the rapid release of topotecan from liposomes could
result in empty (drug-free) liposomes or drug-depleted
liposomes in the blood circulation. The interaction of
such drug-free or drug-depleted liposomes with the
B cells in spleen could induce the production of anti-
PEG IgM, rather than inhibiting its production, and lead




It has been reported that the interaction of the immune
system with lipidic nanoparticle therapeutics could
result in hypersensitivity reactions (HSRs) or an infu-
sion reaction, referred to as complement activation-
related pseudoallergy (CARPA), which is classified as
non-IgE-mediated pseudoallergy caused by the activa-
tion of the complement system [21,74–78]. Such HSRs
occur directly upon first exposure to lipid excipients,
including lipid nanoparticles without prior sensitiza-
tion, and the symptoms usually decrease or disappear
on subsequent treatment. Therefore, such immunolo-
gical responses are called ‘pseudoallergy’ [76–78].
CARPA elicits cardiopulmonary reactions that exhi-
bit various symptoms. A representative example is
Doxil®, which is a formulation of DXR encapsulated in
PEGylated liposomes with several clinical approvals
[19,79]. The use of Doxil® has been implicated in acute
infusion reactions in up to 45% of the cancer patients
who receive the drug without premedication with ster-
oids and antihistamines, while 4–7.1% in pre-medicated
patients [80–82]. A number of studies have confirmed
the crucial role of complement activation in the onset of
the HSRs [12,21,83]. Such reactions are observed on the
administration of the first dose of Doxil® administered
via infusion as a result of the activation of the comple-
ment system. The degree of reaction depends on the
rate of infusion: slower infusion, lower reaction. It is not
similar to the type I allergy, which requires prior prim-
ing of the immune system [84]. Table 1 represents
examples of marketed liposomal drugs that have been
reported to cause hypersensitivity reactions.
5.1 Mechanism of CARPA
It is well known that the complement system is respon-
sible for immune regulation in the body; it contributes to
coordination of the adaptive immune response, and it
plays a pivotal role in the immune defense against foreign
intruders [85]. Complement activation as a possible
cause of HSRs, caused by radiocontrast media, was
reported as early as the 1970s [86,87]. Hugli [88] studied
complement activation and described the structures and
roles of anaphylotoxins, primarily C3a and C5a, in com-
plement-mediated adverse drug reactions. In animal stu-
dies, interestingly, they discovered that C3a and C5a are
effective regulators in autonomic and cardiovascular
organ function. Moreover, they suggested that over-
expression of C3a and C5a in complement activation
explains the cardiovascular symptoms and other symp-
toms of anaphylactic reactions [77]. Szebeni reported
that CARPA is an independent class of type I reactions,
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exhibiting receptor-mediated mast cell activation [76].
Several drugs and agents cause CARPA, including radio-
contrast media, liposomal drugs (Doxil®, DaunoXome®
and Ambisome®), and micellar solvents such as the exci-
pient Cremophore EL present in Taxol) [76,77,89,90].
As described above, intravenous injections of lipid-
containing therapeutics could trigger adverse immuno-
logical reactions through complement activation via both
the classical and the alternative pathways, resulting in
CARPA [21,76,87]. The exact mechanism of liposome-
induced CARPA is still being elucidated as it involves
many cellular (including secretory cells, blood cells and
effector cells) and molecular processing (including ana-
phylotoxins and allergomedins). The working hypothesis
is that, upon complement activation, anaphylatoxins
such as C5a and C3a are released, and they activate
macrophages, basophils and mast cells through their
specific receptors. These cells then secrete a variety of
vasoactive inflammatory mediators, referred to as aller-
gomedins, involving tryptase, histamine, platelet-
activating factor (PAF) and leukotrienes (LTB2, LTD4,
LTC4, PGD2, TXA2 and LTE4) [21,91] as shown in
Figure 3. When the complement system is activated,
some of these allergomedins (histamine, PAF, TAX2
and tryptase) are released from the cells. The released
mediators bind to their receptors on autonomic effector
cells such as endothelial cell and smooth muscle cells,
causing their activation, resulting in CARPA [92].
Another possible mechanism for liposome-induced
CARPA is the ‘double hit hypothesis’ [21]. It is proposed
that there are two hits on immune cells (basophils, mast
cells, tissuemacrophages) that regulate CARPA. The first
hit is the anaphylatoxin signal, and the second one is the
direct binding of particles or reaction-trigger drugs to
these cells via surface receptors that are linked to the
signal transduction network, which triggers secretory
responses. The anaphylatoxins lead to secretion of
vasoactive secondary mediators via binding to their
respective receptors (anaphylatoxins receptors, ATR)
on mast cells or pulmonary intravascular macrophages.
In the sameway, direct binding of the PEG on coupled to
liposome surfaces to these cells occurs through surface
receptors or pattern recognition receptors (PRRs), as well
as toll-like receptors (TLR2 and TLR4) or other danger-
signaling receptors (DSRs) on mast cells and macro-
phages that might elicit a secretory response.
5.2 Factors affecting liposome-induced CARPA
5.2.1 Morphological properties of liposome
The finding that Doxil® could trigger a remarkable
increase in SC5b-9 production, whereas free DXR
could not suggest that DXR’s complement activating
effect might be indirect, via modifying the surface of
liposomes [85]. Generally, the presence of low curvature
oval, elongated and irregular liposomes is considered
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multimolecular complexes, such as the C3 convertases
(C4b2b or C3bBb) and C5 convertases (C4b2b3b or
C3bBb3b), and thereby the activation of the complement
system [93]. Morphological evidence of the presence of
elongated crystals of DXR and/or elongated or irregular
liposome morphologies in Doxil®, which causes ovali-
form transitions of spherical vesicles, may explain the
reactogenicity of Doxil®, but does not explain why only
a subset of patients experience symptoms [12,92].
5.2.2 Liposome size
Theoretically, the binding of anti-phospholipid, anti-
cholesterol and anti-PEG antibodies to the liposomes
[94] and subsequent complement activation in the
blood of some patients should be proportional to the
overall surface area of vesicles directly exposed to blood.
Large multilamellar vesicles (LMV) could, theoretically,
elicit a higher hypertensive effect compared to small
unilamellar vesicles (SUV) which have lesser effects
[95,96]. Indeed, increasing the mean diameter of lipo-
somes, increases the flat surfaces, due to low-curvature of
the vesicle, and permits the efficient binding of natural
antibodies including pre-existing anti-PEG antibodies to
liposomes surface as a result of favorable positioning of
epitopes such as PEG. Another factor could be the spatial
arrangement of surface-bound antibodies on the flat sur-
face of liposomes because the activation of complement
protein 1 (C1) needs multiple IgG molecules to be
aligned in a special parallel configuration [94]. On the
contrary, Pedersen et al. [97] reported that dextran-
conjugated particles with mean diameters of 250 nm
had more pronounced complement activation than par-
ticles with mean diameter of 600 nm.
5.2.3 Liposome composition and surface charge
Liposomal surface charge affects the extent of com-
plement activation induced by liposomes. Positively
charged liposomes show increased interactions with
serum/plasma proteins, compared to neutral or nega-
tively charged liposomes, and exhibited increased
complement activation in an in vitro human comple-
ment assay [11,92]. In mouse models in vivo,
Figure 3. Mechanism of CARPA.
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intravenous administration of cationic liposomes
caused pulmonary inflammation and hepatotoxicity
as a consequence of complement activation, while
neutral liposomes did not [98,99].
Moghimi et al. [100] demonstrated that the nega-
tively charged phosphor diester moiety of methoxy
PEG grafted to DSPE, commonly incorporated into
PEGylated liposomes, is responsible for the increased
complement activation observed in PEGylated DPPC
liposomes. This is confirmed by the reduction in com-
plement activation by non-PEGylated liposomes and
inhibition of complement activation when this acidic
moiety is methylated. Therefore, the appropriate selec-
tion of lipids used for liposome preparation could
reduce potential toxicities of liposome formulations.
In animal models of CARPA, Ambisome®, contain-
ing HSPC and anionic DSPG, used clinically for the
treatment of systemic fungal infections, caused more
infusion reactions than its identically sized, uncharged
PEGylated counterpart [11]. Nevertheless, it has been
reported that PEGylated liposomes with negative sur-
face zeta potentials, including Doxil®, could activate the
complement system [11,93]. The finding that LMV
prepared from negative charged phospholipids, distear-
oyl phosphatidylglycerol (DSPG) had more vasoactive
effect than the electroneutral LMV composed of only
dimyristoyl phosphatidylcholine (DMPC) is consistent
with the results indicating that charged liposomes are
capable of activating complement system to a higher
degree than uncharged ones [101,102].
It is proposed that the pulmonary hypertension
induced by liposomes occurs through the activation of
classical and alternative pathways of the complement
system via antibodies and C3 binding [94]. The presence
of cholesterol in LMV at a level <45 mol% did not affect
the pulmonary reaction, while >45 mol% cholesterol
increased the complement activation in such a degree
that a very small amount (5 mg) of these vesicles lead to
circulatory collapse with spontaneous death in almost
50% of the pigs [94]. The possible explanation for this
difference is that the excess cholesterol in the vesicles
would become exposed on the surface of liposomemem-
brane as microcrystal aggregates and therefore become
more susceptible to interaction with naturally occurring
anti-cholesterol antibodies [94]. Accordingly, it could be
concluded that vasoactivity of vesicles is correlated with
surface zeta potentials (positive or to a lesser extent
negative) and improperly formulated vesicles containing
cholesterol levels in excess of what can be accommodated
in phospholipid membranes.
5.2.4 Route and speed of intravenous
administration
The intensity of the pulmonary hypertension is influ-
enced by the route and rate of administration. It has been
reported that administration of SUV in pigs by slow
infusion suppressed the pulmonary hypertensive effect,
compared to the effect observed with bolus intravenous
injections [94]. These results can be accounted for by the
elevation of blood anaphylatoxins levels, which are con-
sidered the rate limiting mediator in pulmonary vasoac-
tivity [103]. Studies showed that the steady-state level of
functional anaphylatoxins is controlled by the produc-
tion rate and clearance rate of C3a andC5a in the plasma.
Since the clearance rate is unaffected by the method of
administration, anaphylatoxins levels in the blood would
be proportional to the degree of complement activation
induced by the injected liposomes, as well as the speed of
liposome injection. The clinical protocol for administra-
tion of Doxil® calls for a slow rate of infusion, which,
along with pre-medication with corticosteroids, accounts
for the low or absent infusion reactions seen in amajority
of patients [92,104].
6. Toxicity relating to ABC phenomenon and
CARPA
A few researchers have reported that repeated injec-
tion of empty PEGylated liposomes altered their
pharmacokinetic behavior (the ABC phenomenon),
which might lead to lower therapeutic efficacy and
even unexpected side effects, if cytotoxic drugs were
encapsulated [58,72,73]. In other than liposomes, it
has been reported that repeated injections of long
circulating organic-inorganic hybrid nanoparticles
induced the ABC phenomenon, which substantially
attenuated the passive targeting of 64Cu-labeled
PEGylated nanoparticles in a murine model of per-
ipheral arterial disease [105]. In addition, the
PEGylated liposomal formulations including Doxil®,
Ambisome®, Abelect®, and Amphocyl® showed acute
immune toxicity represented in non-IgE mediated
hypersensitivity reactions (CARPA) in a small per-
centage of individuals treated for the first time in the
absence of pre-medication [21,75,94].
7. Approaches for eliminating or reducing
the ABC phenomenon and CARPA
The development of novel approaches to reduce the
immunogenic properties of PEGylated liposomes may
be necessary for some future clinical applications of
liposomes.
7.1. Approaches to eliminate or weaken the
induction of the ABC phenomenon chemical
modification of PEG moiety
Since all currently approved PEGylated liposomal
formulations contain methoxy poly (ethylene glycol)
(mPEG2000) coupled to DSPE, one strategy to attenu-
ate PEG immunogenicity may be structural modifica-
tion of the PEG moiety. Sherman et al. [106], in
animal experiment (rabbits), examined the
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contribution of the methoxy group (-OCH3) to
immune responses to proteins conjugated to mPEG
and emphasized the potential advantages of replacing
mPEG with hydroxyl PEG (HO-PEG). Recently, in
mice, we investigated the impact of the PEG terminal
groups on the induction of anti-PEG IgM (immuno-
genicity), on the cross-reactivity of induced anti-PEG
IgM (antigenicity), and on the systemic clearance
of second doses of modified liposomes. We intro-
duced various functional groups, amino (NH2),
methoxy (OCH3), carboxyl (COOH), and hydroxyl
(OH), at the chain ends of PEG to investigate the
effect on anti-PEG IgM induction. We showed that
liposomes modified with HO-PEG induced low levels
of anti-PEG IgM following a single intravenous injec-
tion. However, upon repeated injections, an initial
dose of HO-PEG liposomes triggered the enhanced
clearance of a second dose. In vitro studies demon-
strated that HO-PEG liposomes activated the com-
plement system in the presence of anti-PEG IgM.
This clearly indicates that anti-PEG IgM induced by
an initial dose triggered the rapid clearance of
a subsequent dose via complement activation [107].
7.1.1 Use of alternative polymers
The use of alternative polymers, such as polyglycerol
[108,109], polyvinyl alcohol, polyvinylpyrrolidone
(PVP) [110] or polyacrylamide (PAM) [111] instead
of PEG, to impart long circulation times to liposome
is a promising approach to reduce the induction of
the ABC phenomenon. It was reported that surface
modification of liposomes with polyglycerol 760
coupled to DSPE significantly attenuated anti-PEG
and anti-polyglycerol antibody response. The hydro-
xylmethyl side group, in the repeating (OCH2CH
(CH2OH)) n – subunit of the polyglycerols might
sterically prevent the binding of modified liposomes
to immunoglobulin on splenic B cells and conse-
quently hinder B cells stimulation. Consequently,
polyglycerol coupled to the liposome surface could
reduce the clearance of second and subsequent doses
when this is a problem [108].
7.1.2 Insertion of gangliosides into PEGylated
liposomes
Insertion of gangliosides from a porcine brain (oligo-
glycosylceramides; a mixture of GM1, GD1a, GD1b
and GT1b, containing sialic acid) into PEGylated
liposomes at a concentration of 10% of the total
phospholipids also shows activity in reducing the
ABC effect [112]. This is attributed to the immuno-
suppressive effect of gangliosides, functioning as
Siglec ligands (lectin-like adhesion proteins on
macrophages) on reactive B cells that result in B cell
tolerance and decreased anti-PEG IgM production.
Accordingly, liposomal membrane modification with
clinically acceptable gangliosides might be worth
exploring further.
7.1.3 Alteration of administration regimen
A number of studies have confirmed that the magni-
tude of ABC phenomenon could be reduced by prior
administration of large lipid dose of drug-free lipo-
somes and/or prolongation of the time interval
between two injections (3 weeks or more)
[61,64,113]. These approaches might be considered
on a case by case basis in those applications where the
ABC phenomenon is shown to be a problem.
7.2. Approaches to alleviate CARPA patient
prophylactic conditioning
Premedication with steroids and anti-allergic drugs
such as ibuprofen, acetaminophen, antihistaminic
and dexamethasone can mitigate the severity of
CARPA and this is currently the standard clinical
approach [87,114]. Besides that, adjusting the infu-
sion protocol to start with low infusion rate proved to
be useful [104,115]
7.2.1 Manipulation of the physicochemical
properties of liposomes
The physicochemical properties of liposomes could
influence the intensity of complement activation. As
described above, certain characteristic of liposomes
can increase the extent of complement activation.
Surface charge, especially positive surface zeta poten-
tials, increasing size, as well as PEGylation all have
been implicated in liposome-induced complement
activation [94,100,116]. Homogeneous SUV of ~100
nm diameter, with slightly negative surface zeta
potentials (to prevent aggregation), have been
shown to be the least reactogenic liposomal formula-
tions [117]. Formulation strategies focused on the
immunogenicity of mitigating liposomes include
methylation of the oxygen moiety of the mPEG poly-
mer [100], or the use of other non-ionic polymers
and lipid conjugates, such as mPEG-substituted syn-
thetic ceramides [118].
7.2.2 Use of complement inhibitor factor H (FH)
Intravenous administration of PEGylated liposomes
activates the complement system, which results in
symptoms of CARPA that could be clinically signifi-
cant. These CARPA-genic reactions can be sup-
pressed by engineered or natural complement
inhibitors such as regulatory factor H (FH). FH,
a 155-kDa plasma glycoprotein, is considered to be
a main inhibitor of the alternative pathway in com-
plement activation, which consists of complement
control protein domains (CCPs). FH can inhibit
complement activation in both body fluids and host
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cell surfaces (basement membrane and endothelial
cells) and FH levels have an inverse relation with
the severity of HSRs [119]. FH acts by hindering the
production of C3bBb convertase, by stimulating the
dissociation of convertase (if previously formed), and
by acting with the protease factor I in the enzymatic
inactivation of C3b [120]. It has been reported that
exogenous FH, co-mixed with either Ambisome®
(liposomes containing amphotericin-B) or rituximab®
(anticancer monoclonal antibody), significantly inhi-
bits the complement activation elicited by
Ambisome® as well as rituximab® in vitro [119].
Furthermore, mini-FH, an artificial form of FH,
exhibited a more pronounced inhibitory effect on
Ambisome® and rituximab®-induced complement
activation, in vitro. Consequently, FH is considered
as a potent inhibitor of complement activation which
could be a promising approach in prevention of
CARPA.
7.2.3 Tachyphylaxis induction with empty
PEGylated liposomes
Induction of tachyphylaxis or immune tolerance is con-
sidered a promising approach to avert hypersensitivity
reactions triggered by liposomal formulations [121]. It is
reported that short infusions (15–30 min) of a placebo of
Doxil®, Doxebo® (Doxil–like empty (drug-free) lipo-
somes composing of HSPC, Chol and mPEG2000-
DSPE), in a pig model substantially decreased, or almost
abolished, the anaphylactic reactions to a subsequent
Doxil® dose, and this effect continued for 24 h post
Doxebo® administration [121]. This can be explained as
resulting from the consumption of early mediators of
HSRs such as pre-existing anti-PEG antibodies or inter-
rupting the signaling process in the cells that contribute
to this reaction. Consequently, tachyphylaxis induction
might be beneficial for prevention of CARPA induced by
lipids.
8. Conclusions
Immunological response to PEGylated liposomes is
a phenomenon that should be taken into account
when expanding clinical uses of PEGylated liposomes
in some circumstances, since the ABC phenomenon
might decrease the therapeutic effect of second and
subsequent liposome doses. The appearance of
CARPA not controlled by pre-medications and slow-
ing the infusion rate, might cause worrying side
effects when the patients are treated with lipid-
containing formulations, including PEGylated liposo-
mal formulations given for the first time.
Accordingly, further understanding of the mechan-
isms underlying these responses, along with various
techniques that can help in the avoidance of these
responses can aid in the design of PEGylated
liposomes and other lipid-based nanocarriers for
future applications.
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